Clean Science and Technology Ltd (BOM:543318) (Q1 2027) Earnings Call Highlights: Record Sales ...

Negative Points

• The company faced significant geopolitical headwinds, including raw material supply chain disruptions and non-availability of shipping vessels, which impacted timely exports and led to a 6% YoY decline in standalone sales.

• Raw material costs in China were not impacted as much as in India, creating a competitive disadvantage, and the company was unable to pass on 100% of input cost increases to customers due to long-term contracts.

• The Performance Chemical 2 plant has been delayed due to labor issues and is now expected to commercialize in November, with major revenue contribution only expected from Q1 FY28.

• The company experienced a two-week production shutdown in Q1 due to a key Indian supplier's facility closure, which negatively impacted volumes and revenue.

• Raw material price volatility remains a persistent issue, and management noted that while supply availability has improved, profitability could still be affected by fluctuating crude oil prices and geopolitical tensions.

• The company had to infuse approximately INR100 crores into its subsidiary during the quarter, bringing total investment to INR850 crores, indicating significant capital requirements for the HALS business.

Q & A Highlights

Q: What is the revenue potential and structure of the strategic collaboration with Swiss partner Geneus Chem for advanced HALS? A: Siddharth Sikchi, MD and Promoter, clarified that Geneus Chem is a technology-driven company with patented, advanced NOR HALS products. The collaboration involves technology transfer to Clean Science, with production at Clean Fino Chem and joint marketing under a co-branding arrangement. The revenue potential from this partnership is INR300-350 crores over the next 3-4 years, with peak annual revenue potentially around INR100 crores. The company will invest approximately INR25 crores in CapEx for this product line, with production expected to start in Q3 FY27.

Q: What were the HALS volume and pricing dynamics in Q1 FY27, and what is the realistic revenue target for FY27? A: Sanjay Parnerkar, CFO, stated that HALS volumes were approximately 1,000 tons in the quarter. The product mix improved significantly, with HALS 770 contribution dropping from 50% to 35%, moving toward higher grades. Average prices improved from INR440 to INR550. Siddharth Sikchi confirmed that annualized revenue from HALS would reach INR250-300 crores, which is a comfortable target for FY27.

Q: Is the improved gross profit margin of 43-45% sustainable, and what drove the improvement? A: Siddharth Sikchi confirmed the margin improvement is sustainable. The company had no advantage from cheap raw materials. Instead, the margin improvement was driven by moving to higher-grade products and improving operational efficiencies. This was not a one-off benefit from low-cost inventory.

Q: What caused the YoY decline in legacy business volumes, and has the situation normalized? A: Siddharth Sikchi explained that the decline was due to supply-side headwinds. The primary raw material supplier in India had to shut down for approximately two weeks due to nonavailability of propylene. Additionally, shipping vessel nonavailability impacted timely exports. Demand remains steady, and while raw material price volatility persists, supply availability has improved in Q2.

Q: What is the significance of the five-year supply agreement with Kemin, and what volume increase is expected? A: Siddharth Sikchi explained that Kemin, a global formulator for the pet food industry, has been a customer for over a decade. The new definitive five-year contract makes Clean Science the primary supplier of BHA, BHT, TBHQ, and AP to all Kemin's global locations. The offtake is expected to increase by 20-40%, starting within the next 2-3 months. This agreement requires additional capacity investments and effectively preempts competitors from entering this alliance.

Q: How does the Geneus Chem collaboration differ from existing HALS products, and what is the market opportunity? A: Siddharth Sikchi explained that current HALS products are hydroxy-based, while the new collaboration involves alkoxy HALS (NOR), which are higher-grade and more expensive. These products are used in harsher environments like agricultural films where pesticides, sulfur, and chlorine are present. This represents a completely new market segment for Clean Science, currently dominated by BASF. The collaboration also enables cross-selling of existing HALS grades to the same customers.

Q: What is the status of the hydroquinone and catechol plant stabilization and Performance Chemical 2? A: Siddharth Sikchi stated that the hydroquinone and catechol plant stabilization is largely complete. Customer approvals have been received, and commercial supplies are ramping up, with revenue expected from August-September. Performance Chemical 2 commercialization has been delayed to November due to labor issues, with the stabilization phase running through March and major revenue expected from Q1 FY28.

Q: What is the competitive landscape for HALS, and how is export penetration progressing? A: Siddharth Sikchi identified BASF and Sabo as major European competitors, with Rianlon and Suqian (Unitechem) as Chinese competitors. Export penetration for HALS has improved significantly, with exports now contributing nearly 50% of HALS sales compared to entirely domestic sales in the first year. This reflects successful customer approvals and commercial shipments to large international accounts.

Q: What is the current domestic-export mix for the standalone business, and how are raw material cost increases being managed? A: Siddharth Sikchi confirmed the standalone domestic-export mix is 65-35. Regarding raw material cost increases from the Middle East crisis, the company has not been able to pass on 100% of the increases. Long-term contracts are being respected, and only a percentage of price increases have been passed through in some cases. Raw material price volatility remains a concern for profitability, though supply availability has improved.

Q: What is the long-term structural plan for the wholly-owned subsidiary Clean Fino Chem? A: Siddharth Sikchi stated that all future products and new lines will be housed in Clean Fino Chem. The subsidiary has received approximately INR100 crores in capital infusion during the quarter, bringing total investment to approximately INR850 crores. CFCL has reached an important milestone by becoming operationally self-sustaining, having fully recovered its operating expenses, and is now shifting from the investing phase to the monetizing phase.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .